277 related articles for article (PubMed ID: 31758962)
1. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice.
Han X; Cai C; Xiao Z; Quarles LD
J Mol Cell Cardiol; 2020 Jan; 138():66-74. PubMed ID: 31758962
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
Leifheit-Nestler M; Grabner A; Hermann L; Richter B; Schmitz K; Fischer DC; Yanucil C; Faul C; Haffner D
Nephrol Dial Transplant; 2017 Sep; 32(9):1493-1503. PubMed ID: 28339837
[TBL] [Abstract][Full Text] [Related]
3. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
Grabner A; Amaral AP; Schramm K; Singh S; Sloan A; Yanucil C; Li J; Shehadeh LA; Hare JM; David V; Martin A; Fornoni A; Di Marco GS; Kentrup D; Reuter S; Mayer AB; Pavenstädt H; Stypmann J; Kuhn C; Hille S; Frey N; Leifheit-Nestler M; Richter B; Haffner D; Abraham R; Bange J; Sperl B; Ullrich A; Brand M; Wolf M; Faul C
Cell Metab; 2015 Dec; 22(6):1020-32. PubMed ID: 26437603
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene.
Han X; Ross J; Kolumam G; Pi M; Sonoda J; King G; Quarles LD
J Am Soc Nephrol; 2018 Jan; 29(1):69-80. PubMed ID: 28993502
[TBL] [Abstract][Full Text] [Related]
5. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
[TBL] [Abstract][Full Text] [Related]
6. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.
Grabner A; Schramm K; Silswal N; Hendrix M; Yanucil C; Czaya B; Singh S; Wolf M; Hermann S; Stypmann J; Di Marco GS; Brand M; Wacker MJ; Faul C
Sci Rep; 2017 May; 7(1):1993. PubMed ID: 28512310
[TBL] [Abstract][Full Text] [Related]
7. Hypericin Alleviates Chronic Kidney Disease-induced Left Ventricular Hypertrophy by Regulation of FGF23-FGFR4 Signaling Pathway.
Liu M; Cheng L; Ye Q; Liu H; Shu C; Gao H; Liu X; Zhang X; Chen G
J Cardiovasc Pharmacol; 2024 Jun; 83(6):588-601. PubMed ID: 38547517
[TBL] [Abstract][Full Text] [Related]
8. Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4.
Gattineni J; Alphonse P; Zhang Q; Mathews N; Bates CM; Baum M
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F351-8. PubMed ID: 24259513
[TBL] [Abstract][Full Text] [Related]
9. FGFR3 and FGFR4 do not mediate renal effects of FGF23.
Liu S; Vierthaler L; Tang W; Zhou J; Quarles LD
J Am Soc Nephrol; 2008 Dec; 19(12):2342-50. PubMed ID: 18753255
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner.
Graves JM; Vallejo JA; Hamill CS; Wang D; Ahuja R; Patel S; Faul C; Wacker MJ
Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2283-H2294. PubMed ID: 33929896
[TBL] [Abstract][Full Text] [Related]
11. Direct and indirect effects of fibroblast growth factor 23 on the heart.
Nakano T; Kishimoto H; Tokumoto M
Front Endocrinol (Lausanne); 2023; 14():1059179. PubMed ID: 36909314
[TBL] [Abstract][Full Text] [Related]
12. Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease.
Yanucil C; Kentrup D; Campos I; Czaya B; Heitman K; Westbrook D; Osis G; Grabner A; Wende AR; Vallejo J; Wacker MJ; Navarro-Garcia JA; Ruiz-Hurtado G; Zhang F; Song Y; Linhardt RJ; White K; Kapiloff MS; Faul C
Kidney Int; 2022 Aug; 102(2):261-279. PubMed ID: 35513125
[TBL] [Abstract][Full Text] [Related]
13. Cardiac Fibroblast Growth Factor 23 Excess Does Not Induce Left Ventricular Hypertrophy in Healthy Mice.
Leifheit-Nestler M; Wagner MA; Richter B; Piepert C; Eitner F; Böckmann I; Vogt I; Grund A; Hille SS; Foinquinos A; Zimmer K; Thum T; Müller OJ; Haffner D
Front Cell Dev Biol; 2021; 9():745892. PubMed ID: 34778257
[TBL] [Abstract][Full Text] [Related]
14. FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-β autoinduction.
Smith ER; Holt SG; Hewitson TD
Int J Biochem Cell Biol; 2017 Nov; 92():63-78. PubMed ID: 28919046
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 23 and Klotho contribute to airway inflammation.
Krick S; Grabner A; Baumlin N; Yanucil C; Helton S; Grosche A; Sailland J; Geraghty P; Viera L; Russell DW; Wells JM; Xu X; Gaggar A; Barnes J; King GD; Campos M; Faul C; Salathe M
Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29748308
[TBL] [Abstract][Full Text] [Related]
16. FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model.
Xiao Z; King G; Mancarella S; Munkhsaikhan U; Cao L; Cai C; Quarles LD
JCI Insight; 2019 Dec; 4(23):. PubMed ID: 31801907
[TBL] [Abstract][Full Text] [Related]
17. Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.
Li H; Martin A; David V; Quarles LD
Am J Physiol Endocrinol Metab; 2011 Mar; 300(3):E508-17. PubMed ID: 21139072
[TBL] [Abstract][Full Text] [Related]
18. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.
Gattineni J; Bates C; Twombley K; Dwarakanath V; Robinson ML; Goetz R; Mohammadi M; Baum M
Am J Physiol Renal Physiol; 2009 Aug; 297(2):F282-91. PubMed ID: 19515808
[TBL] [Abstract][Full Text] [Related]
19. FGF23 induces left ventricular hypertrophy.
Faul C; Amaral AP; Oskouei B; Hu MC; Sloan A; Isakova T; Gutiérrez OM; Aguillon-Prada R; Lincoln J; Hare JM; Mundel P; Morales A; Scialla J; Fischer M; Soliman EZ; Chen J; Go AS; Rosas SE; Nessel L; Townsend RR; Feldman HI; St John Sutton M; Ojo A; Gadegbeku C; Di Marco GS; Reuter S; Kentrup D; Tiemann K; Brand M; Hill JA; Moe OW; Kuro-O M; Kusek JW; Keane MG; Wolf M
J Clin Invest; 2011 Nov; 121(11):4393-408. PubMed ID: 21985788
[TBL] [Abstract][Full Text] [Related]
20. Exploring the implications of blocking renin-angiotensin-aldosterone system and fibroblast growth factor 23 in early left ventricular hypertrophy without chronic kidney disease.
Watanabe K; Fujii H; Okamoto K; Kono K; Goto S; Nishi S
Front Endocrinol (Lausanne); 2023; 14():1276664. PubMed ID: 38174329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
